1. Introduction
Collateral vessels can be found around renal cell carcinoma (RCC). These vessels are enlarged renal capsular veins, which become macroscopically visible in computed tomography (CT) or magnetic resonance imaging (MRI) studies (
Figure 1).
Collateral vessels adjacent to RCC are poorly investigated, and the significance of this finding is not fully understood.
Gonadal vein recruitment is more frequently associated with RCC located at the lower renal pole [
1]. On the other hand, tumors of the upper renal pole usually have a different drainage route, flowing into the adrenal and lower phrenic veins [
1].
A CT study performed on 58 RCC patients showed that 26 patients had peritumoral collateral vessels, of which 18 had outflow through the gonadal vein [
1]. This finding was present in tumors greater than 5 cm in diameter (18/18), more frequently in males (15/18), in tumors of the right kidney (12/18) and at the lower pole (15/18) [
1].
Moreover, collateral vessels were found to be associated with greater blood loss during surgery for RCC (mean volume of 1078 mL vs. 304 mL) [
1] and have been linked to cancer staging in RCC patients, possibly reflecting a sign of locally advanced disease (i.e., T stage > T3a) [
2].
The most frequent grading system in clear cell RCC (ccRCC) and papillary RCC is the four-tiered Fuhrman system (I, II, III and IV) [
3]. A simplified two-tiered Fuhrman grade system has been proposed by dividing the ranks into low grade (I and II) and high grade (III and IV) [
4]. It has been shown to have the same specificity in predicting mortality as the traditional four-tiered Fuhrman grade system but with greater reproducibility and less variability for pathologists [
4]. High-grade tumors have a greater risk of post-operative recurrence [
5].
The possible association between peritumoral collateral vessels adjacent to RCC and the Furman grade has never been explored to date.
Herein, we test the hypothesis that the presence of peritumoral collateral vessels in perinephric adipose tissue adjacent to ccRCC is indicative of a high Furman grade (i.e., III and IV).
2. Materials and Methods
The study design was cross-sectional observational. All the procedures were retro-spective and were in agreementagreed with the Declaration of Helsinki.
CT images and data of ccRCC patients were acquired at multiple centers and re-trieved from The Cancer Imaging Archive (TCIA) [
6,
7,
8]. The TCIA project received approval of the Institutional Review Board. This subsequent retrospective analysis was on the publicly available, anonymized data and did not require further review due to previous protections implemented by TCIA. All the subjects enrolled signed a written informed consent.
Between November 2019 and February 2020, a total of 267 patients with histological diagnoses of ccRCC were retrospectively analyzed and selected based on medical history, CT images and the exclusion criteria. The cohort was selected among consecutive patients with kidney cancer undergoing CT for disease staging.
Exclusion criteria for the ccRCC patients were as follows: patients with previous renal ablation, heminephrectomized and nephrectomized patients and patients with congenital solitary kidney. These categories of patients were excluded because previous interventions, procedures or congenital anatomical variants could change the macroscopic vascular architecture, making the anatomy difficult to compare. Moreover, we also excluded cirrhotic patients with collateral vessels due to the macroscopically abnormal vascular architecture. Finally, we excluded patients who had undergone chest CT only and patients who had undergone MRI examination only. Specifically, the latter patients were excluded to consistently and systematically investigate peritumoral vessels using the same imaging technique, given the well-known greater spatial resolution for the CT images.
3. CT Analysis
All ccRCC selected patients underwent CT examination. All CT images were evaluated and analyzed by a consensus of two radiologists (F.G. and C.A.M., with 5 years and 9 years of experience, respectively) blinded to the clinical data. Imaging analysis, performed on the venous phase in all the cases, was aimed at assessing the presence or absence of peritumoral collateral vessels. These vessels are defined as dilated and macroscopically visible peritumoral renal capsular veins.
4. Statistical Analysis
Data distribution was verified using the Kolmogorov–Smirnov (KS) test. Then, the Mann–Whitney U test was used to assess differences in tumor size between the low (i.e., I and II) and high (i.e., III and IV) Fuhrman grade groups.
A chi-squared test with Yates correction was used to detect whether the distribution of ccRCC patients showed a statistically significant difference. Particularly, we focused on presence or absence of collateral vessels and low or high Fuhrman grades.
A subanalysis was carried out, dividing the groups according to gender.
Then, to assess the impact of tumor size and peritumoral collateral vessels on the Fuhrman grade, we performed a subanalysis grouping the patients with peritumoral collateral vessels according to the median value of the tumor size (i.e., above or below).
Finally, we verified the distribution of patients with or without peritumoral collateral vessels with respect to the low (i.e., T1 and T2) or high (i.e., T3 and T4) staging.
5. Results
A total of 190 ccRCC patients were included in the study, following the exclusion criteria. The descriptive data of the patients are summarized in
Table 1.
There was a statistically significant (p < 0.0001) greater tumor size in the high Fuhrman grade group (n = 112) compared with the low Fuhrman grade group (n = 78).
Among the ccRCC patients, 47 showed an absence of collateral vessels and low Fuhrman grades (ccRCCal), 31 had the presence of collateral vessels and low Fuhrman grades (ccRCCpl), 39 had an absence of collateral vessels and high Fuhrman grades (ccRCCah) and, lastly, the presence of collateral vessels and high Fuhrman grades were found in 73 patients (ccRCCph). The chi-squared statistic with Yates correction showed statistically significant different distribution due to greater number of patients with high Fuhrman grades in the group with collateral vessels (
p < 0.001) (
Figure 2).
Similar results were found with male patients (MccRCCal
n = 33; MccRCCpl
n = 18; MccRCCah
n = 27 and MccRCCph
n = 49) with statistically significant different distribution (
p < 0.005) (
Figure 3). Conversely, no statistically significant differences (
p = 0.31) were detected in the subanalysis performed with the female patient ccRCC subgroups (FccRCCal
n = 14; FccRCCpl
n = 14; FccRCCah
n = 12 and FccRCCph
n = 23).
Non-significant results (p = 0.13) were found by sub-grouping patients with ccRCC and peritumoral collateral vessels according to the median value (i.e., 7.2 cm) of tumor size (low Furhman grade and size < median n = 20; low Furhman grade and size > median n = 12; high Furhman grade and size < median n = 32; high Furhman grade and size > median n = 40).
Lastly, there was a statistically significant (p < 0.0001) different distribution of collateral vessels according to disease staging, mainly due to the lower presence of patients with high staging (i.e., T3 and T4) and lack of peritumoral collateral vessels (ccRCCa and low stage n = 79; ccRCCp and low stage n = 49; ccRCCa and high stage n = 7; and ccRCCp and high stage n = 55).
6. Discussion
This is a large series study showing a novel association between collateral vessels in ccRCC male patients and high Fuhrman grades.
The Fuhrman grade is the most widely used histological grading system for ccRCC [
3]. Several studies investigated signs that could predict Fuhrman grades in ccRCC using a non-invasive imaging-based approach [
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19].
Zhu YH et al., measured the portion of the lesion that exhibited greater contrast enhancement and found that low contrast enhancement during the corticomedullary phase correlated with a high Fuhrman grade [
14]. Vargas HA et al., reported that the correlation between the Fuhrman grade and contrast enhancement was significant only when measured in the entire lesion, compared with the portion with greater contrast enhancement on a single slice [
15].
A further radiomics study showed that data obtained in the corticomedullary and nephrographic phases, separate or combined, could predict the Fuhrman grade in ccRCC [
16]. Regarding small ccRCCs (<4 cm), no correlation was found between lesion contrast enhancement and the histological grade [
17].
Birnbaum et al., reported that the majority of low-grade RCCs showed sharp or slightly irregular margins [
18]. Furthermore, a study conducted by Ro et al., showed that defined margins are associated with less aggressive RCCs due to less infiltrative behavior [
19]. On the other hand, no significant correlations were found between the morphological characteristics of the lesion and the Fuhrman grades in the small RCCs, probably due to the sample being comprised by tumors smaller than 4 cm [
17].
Unenhanced CT found that low lesion attenuation was a predictor of a low Fuhrman grade. This low attenuation probably reflects the intracellular lipids content [
17]. In fact, histological ccRCC can be rich in intracytoplasmic lipids and glycogen; the presence of intracytoplasmic lipids gives the characteristic “clear” appearance of ccRCC [
15]. It has been shown that there is an inverse relationship between the histological grade and intra-cellular lipid droplets [
20,
21].
Additionally, Yao et al., showed that low-grade ccRCCs exhibited greater expression of adipose differentiation-related protein (ADFP), a protein involved in the uptake of fatty acids and the formation of intracellular lipid droplets, compared with high-grade ccRCCs. Increased ADFP expression correlates with increased intracytoplasmic lipid accumulation in low-grade ccRCC compared with high-grade ccRCC [
22,
23].
The non-invasive imaging approach with CT allows a correct qualitative and quantitative assessment of the tissues [
24]. An interesting paradigm is based on the analysis of peritumoral tissues, such as local composition changes of perinephric fat with collateral vessels, or the assessment of whole-body imaging composition [
25,
26,
27,
28,
29,
30,
31].
Here, we confirm the known association between greater ccRCC tumor size and a high Fuhrman grade [
13]. Moreover, in the present study, we demonstrated for the first time a link between peritumoral collateral vessels and high Fuhrman grades in patients with ccRCC. The presence of collateral vessels can be explained as inability of the renal vein to drain venous blood also due to a tumor-related unbalance caused by an increase total size, cellularity and blood demand. These findings might cause dilation of the renal capsular veins, becoming macroscopically evident as collateral vessels in CT or MRI studies. Furthermore, the abnormal cellular architecture of the tumor due to hypercellularity diverts the blood flow toward “alternative routes” (e.g., dilated and macroscopically visible renal capsular veins). Taken together, these mechanisms might explain the presence of collateral vessels in RCCs with high Fuhrman grades.
CcRCC can harbor inactivating mutations (or less commonly by ipermethylation) of the maternal or paternal copies of the Von Hippel Lindau (VHL) gene. When the VHL gene is inactive, the accumulated HIFα upregulates the transcription of genes that respond to tumorigenic hypoxia, including vascular endothelial growth factor A (VEGFA) and encoding VEGF, which stimulates the formation of blood vessels [
32,
33]. With respect to the change of vascular architecture due to the activity of VEGF, further studies will have to evaluate the relationship between perinephric fat collateral vessels and VEGF expression in ccRCC patients. Moreover, it would be interesting to assess whether hybrid genes formed by two previously independent genes (i.e., fusion genes) might play a role in the development of peritumoral collateral vessels adjacent to ccRCC.
The limit of this study is relying on the low number of ccRCC female patients, which does not allow for providing definitive answers on the possible association of peritumoral collateral vessels and high histological grades in this category of patients. Moreover, clinical variables such as the body mass index (BMI), data on R0/R1 resection and survival outcomes were not available due to the retrospective nature of the study.
Further studies will be conducted involving a larger sample of ccRCC female patients and with multiple clinical variables to increase the generalizability of the results.
7. Conclusions
This study shows a novel association between peritumoral collateral vessels in perinephric adipose tissue and high Fuhrman grades (i.e., III and IV) in male patients with ccRCC. Thus, peritumoral collateral vessels adjacent to ccRCC can be considered a diagnostic clue, suggestive of a more aggressive disease.
Author Contributions
Conceptualization, F.G. and C.A.M.; methodology, F.G. and C.A.M.; software, F.G. and C.A.M.; validation, F.G., L.G.Q., C.B., R.F.G. and C.A.M.; formal analysis, F.G. and C.A.M.; investigation, F.G. and C.A.M.; resources, F.G. and C.A.M.; data curation, F.G., C.B. and C.A.M.; writing—original draft preparation, F.G. and C.A.M.; writing—review and editing, F.G. and C.A.M.; visualization, F.G. and C.A.M.; supervision, F.G., M.I.v.B.H., B.B.Z. and C.A.M.; project administration, F.G. and C.A.M. All authors have read and agreed to the published version of the manuscript.
Funding
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Institutional Review Board Statement
All the procedures were retrospective and agreed with the Declaration of Helsinki. CT images and data of ccRCC patients were retrieved from The Cancer Imaging Archive (TCIA). The TCIA project received approval of the Institutional Review Board. This subsequent retrospective analysis was on the publicly available, anonymized data and did not require further review due to previous protections implemented by TCIA.
Informed Consent Statement
All the subjects enrolled signed a written informed consent.
Data Availability Statement
Conflicts of Interest
The authors declare that they have no conflict of interest.
References
- Murphy, B.; Gaa, J.; Papanicolaou, N.; Lee, M. Gonadal Vein Recruitment in Renal Cell Carcinoma: Incidence, Pathogenesis and Clinical Significance. Clin. Radiol. 1996, 51, 797–800. [Google Scholar] [PubMed]
- Bradley, A.J.; MacDonald, L.; Whiteside, S.; Johnson, R.J.; Ramani, V.A.C. Accuracy of preoperative CT T staging of renal cell carcinoma: Which features predict advanced stage? Clin. Radiol. 2015, 70, 822–829. [Google Scholar] [PubMed]
- Moch, H.; Cubilla, A.L.; Humphrey, P.A.; Reuter, V.E.; Ulbright, T.M. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs—Part A: Renal, Penile, and Testicular Tumours. Eur. Urol. 2016, 70, 93–105. [Google Scholar] [PubMed]
- Becker, A.; Hickmann, D.; Hansen, J.; Meyer, C.; Rink, M.; Schmid, M.; Eichelberg, C.; Strini, K.; Chromecki, T.; Jesche, J.; et al. Critical analysis of a simplified Fuhrman grading scheme for prediction of cancer specific mortality in patients with clear cell renal cell carcinoma—Impact on prognosis. Eur. J. Surg. Oncol. 2016, 42, 419–425. [Google Scholar]
- Novara, G.; Martignoni, G.; Artibani, W.; Ficarra, V. Grading systems in renal cell carcinoma. J. Urol. 2007, 177, 430–436. [Google Scholar]
- NIH National Cancer Institute. Available online: https://cancergenome.nih.gov/ (accessed on 1 November 2019).
- Akin, O.; Elnajjar, P.; Heller, M.; Jarosz, R.; Erickson, B.; Kirk, S.; Filippini, J. Radiology Data from The Cancer Genome Atlas Kidney Renal Clear Cell Carcinoma [TCGA-KIRC] collection. Cancer Imaging Arch. 2016. [Google Scholar] [CrossRef]
- Clark, K.; Vendt, B.; Smith, K.; Freymann, J.; Kirby, J.; Koppel, P.; Moore, S.; Phillips, S.; Maffitt, D.; Pringle, M.; et al. The Cancer Imaging Archive (TCIA): Maintaining and Operating a Public Information Repository. J. Digit. Imaging 2013, 26, 1045–1057. [Google Scholar]
- Coy, H.; Young, J.R.; Pantuck, A.J.; Douek, M.L.; Sisk, A.; Magyar, C.; Brown, M.S.; Sayre, J.; Raman, S.S. Association of tumor grade, enhancement on multiphasic CT and microvessel density in patients with clear cell renal cell carcinoma. Abdom. Radiol. 2020, 45, 3184–3192. [Google Scholar] [CrossRef]
- Coy, H.; Young, J.R.; Douek, M.L.; Pantuck, A.; Brown, M.S.; Sayre, J.; Raman, S.S. Association of qualitative and quantitative imaging features on multiphasic multidetector CT with tumor grade in clear cell renal cell carcinoma. Abdom. Radiol. 2019, 44, 180–189. [Google Scholar] [CrossRef]
- Lin, F.; Cui, E.-M.; Lei, Y.; Luo, L.-P. CT-based machine learning model to predict the Fuhrman nuclear grade of clear cell renal cell carcinoma. Abdom. Radiol. 2019, 44, 2528–2534. [Google Scholar] [CrossRef]
- Villavicencio, C.P.; Mc Carthy, R.J.; Miller, F.H. Can diffusion-weighted magnetic resonance imaging of clear cell renal carcinoma predict low from high nuclear grade tumors. Abdom. Radiol. 2017, 42, 1241–1249. [Google Scholar] [CrossRef]
- Oh, S.; Sung, D.J.; Yang, K.S.; Sim, K.C.; Han, N.Y.; Park, B.J.; Kim, M.J.; Cho, S.B. Correlation of CT imaging features and tumor size with Fuhrman grade of clear cell renal cell carcinoma. Acta Radiol. 2017, 58, 376–384. [Google Scholar] [CrossRef]
- Zhu, Y.-H.; Wang, X.; Zhang, J.; Chen, Y.-H.; Kong, W.; Huang, Y.-R. Low enhancement on multiphase contrast-enhanced CT images: An independent predictor of the presence of high tumor grade of clear cell renal cell carcinoma. Am. J. Roentgenol. 2014, 203, 295–300. [Google Scholar]
- Vargas, H.A.; Delaney, H.G.; Delappe, E.M.; Wang, Y.; Zheng, J.; Moskowitz, C.S.; Tan, Y.; Zhao, B.; Schwartz, L.H.; Hricak, H.; et al. Multiphasic contrast-enhanced MRI: Single-slice versus volumetric quantification of tumor enhancement for the assessment of renal clear-cell carcinoma fuhrman grade. J. Magn. Reson. Imaging 2013, 37, 1160–1167. [Google Scholar] [CrossRef] [Green Version]
- Shu, J.; Tang, Y.; Cui, J.; Yang, R.; Meng, X.; Cai, Z.; Zhang, J.; Xu, W.; Wen, D.; Yin, H. Clear cell renal cell carcinoma: CT-based radiomics features for the prediction of Fuhrman Grade. Eur. J. Radiol. 2018. [Google Scholar] [CrossRef]
- Choi, S.Y.; Sung, D.J.; Yang, K.S.; Kim, K.A.; Yeom, S.K.; Sim, K.C.; Han, N.Y.; Park, B.J.; Kim, M.J.; Cho, S.B.; et al. Small (<4 cm) clear cell renal cell carcinoma: Correlation between CT findings and histologic grade. Abdom. Radiol. 2016, 41, 1160–1169. [Google Scholar]
- Birnbaum, B.A.; Bosniak, M.A.; Krinsky, G.A.; Cheng, D.; Waisman, J.; Ambrosino, M.M. Renal cell carcinoma: Correlation of CT findings with nuclear morphologic grading in 100 tumors. Abdom. Imaging 1994, 19, 262–266. [Google Scholar]
- Ro, J.Y.; Ayala, A.G.; Sella, A.; Samuels, M.L.; Swanson, D.A. Sarcomatoid renal cell carcinoma: Clinicopathologic. A study of 42 cases. Cancer 1987, 59, 516–526. [Google Scholar]
- Yu, M.; Wang, H.; Zhao, J.; Yuan, Y.; Wang, C.; Li, J.; Zhang, L.; Zhang, L.; Li, Q.; Ye, J. Expression of CIDE proteins in clear cell renal cell carcinoma and their prognostic significance. Mol. Cell. Biochem. 2013, 378, 145–151. [Google Scholar]
- Thoenes, W.; Störkel, S.; Rumpelt, H. Histopathology and classification of renal cell tumors (adenomas, oncocytomas and carcinomas). The basic cytological and histopathological elements and their use for diagnostics. Pathol. Res. Pract. 1986, 181, 125–143. [Google Scholar]
- Yao, M.; Tabuchi, H.; Nagashima, Y.; Baba, M.; Nakaigawa, N.; Ishiguro, H.; Hamada, K.; Inayama, Y.; Kishida, T.; Hattori, K.; et al. Gene expression analysis of renal carcinoma: Adipose differentiation-related protein as a potential diagnostic and prognostic biomarker for clear-cell renal carcinoma. J. Pathol. 2005, 205, 377–387. [Google Scholar] [CrossRef]
- Yao, M.; Huang, Y.; Shioi, K.; Hattori, K.; Murakami, T.; Nakaigawa, N.; Kishida, T.; Nagashima, Y.; Kubota, Y. Expression of adipose differentiation-related protein: A predictor of cancer-specific survival in clear cell renal carcinoma. Clin. Cancer Res. 2007, 13, 152–160. [Google Scholar] [CrossRef] [Green Version]
- Greco, F.; Faiella, E.; Santucci, D.; Mallio, C.A.; Nezzo, M.; Quattrocchi, C.C.; Zobel, B.B.; Grasso, R.F. Imaging of Renal Medullary Carcinoma. J. Kidney Cancer VHL 2017, 4, 1–7. [Google Scholar] [CrossRef] [Green Version]
- Del Buono, R.; Sabatino, L.; Greco, F. Neck fat volume as a potential indicator of difficult intubation: A pilot study. Saudi J. Anaesth. 2018, 12, 7–71. [Google Scholar]
- Greco, F.; Mallio, C.A.; Cirimele, V.; Grasso, R.F.; Zobel, B.B. Subcutaneous adipose tissue as a biomarker of pancreatic cancer: A pilot study in male patients. Clin. Cancer Investig. J. 2019, 8, 10–19. [Google Scholar] [CrossRef]
- Mallio, C.A.; Greco, F.; Pacella, G.; Schena, E.; Zobel, B.B. Gender-based differences of abdominal adipose tissue distribution in non-small cell lung cancer patients. Shanghai Chest 2018, 2, 20. [Google Scholar] [CrossRef]
- Greco, F.; Cirimele, V.; Mallio, C.; Zobel, B.; Grasso, R. Increased visceral adipose tissue in male patients with clear cell renal cell carcinoma. Clin. Cancer Investig. J. 2018, 7, 132–136. [Google Scholar] [CrossRef]
- Greco, F.; Mallio, C.A.; Grippo, R.; Messina, L.; Vallese, S.; Rabitti, C.; Quarta, L.G.; Grasso, R.F.; Zobel, B.B. Increased visceral adipose tissue in male patients with non-clear cell renal cell carcinoma. Radiol. Med. 2020, 125, 538–543. [Google Scholar] [CrossRef]
- Greco, F.; Quarta, L.G.; Grasso, R.F.; Zobel, B.B.; Mallio, C.A. Increased visceral adipose tissue in clear cell renal cell carcinoma with and without peritumoral collateral vessels. Br. J. Radiol. 2020, 16, 20200334. [Google Scholar] [CrossRef]
- Greco, F.; Mallio, C.A. Relationship Between Visceral Adipose Tissue and Genetic Mutations (VHL and KDM5C) in Clear Cell Renal Cell Carcinoma. Radiol. Med. 2021. [Google Scholar] [CrossRef]
- Gossage, L.; Eisen, T.; Maher, E.R. VHL, the story of a tumour suppressor gene. Nat. Rev. Cancer 2015, 15, 55–64. [Google Scholar] [CrossRef] [PubMed]
- Ledford, H.; Callaway, E. Biologists who decoded how cells sense oxygen win medicine Nobel. Nature 2019, 574, 161–162. [Google Scholar] [CrossRef] [PubMed] [Green Version]
| Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).